Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9510128 | 0.87 | CTSB (0.62) | PREPCTSKCTSLCTSBCTSS | |
| SCHEMBL9510140 | 0.86 | PREP (0.62) | PREPCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL10679399 | 0.82 | PREP (0.53) | PREPCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL29925751 | 0.81 | PREP (0.54) | PREPCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL11254461 | 0.81 | PREP (0.61) | PREPCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL8206101 | 0.81 | PREP (0.61) | PREPCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL11261467 | 0.81 | PREP (0.61) | PREPCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL8206098 | 0.81 | PREP (0.61) | PREPCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL3315212 | 0.80 | CTSK (0.59) | CTSKCTSLCTSBCYP1A2CTSS | |
| SCHEMBL9511304 | 0.80 | PREP (0.55) | PREPCTSKCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849650-B2 | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030130188-A1 | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THORSETT EUGENE D (US) | 2003-07-10 | — | — | US | disclosed |
| US-6506782-B1 | Compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta | ATHENA NEUROSCIENCES, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130188-A1 | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, BACE1, IAPP | PREP 51/4885CTSK 273/4885CTSL 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.